Some wounds never get the message to close. A smart wound bandage from Imperial College London is built for exactly those, and it turns the patient’s own body into the pharmacy.

Diabetic foot ulcers affect about 18.6 million people a year. Roughly one in five of those cases ends in amputation of part or all of the foot.


EarthSnap

The material captures healing proteins already sitting in the wound or the blood and holds them still. It lets go only when a repair cell crawls in and pulls.

Why some wounds never heal

Healing runs on growth factors – proteins that tell cells to move, multiply and rebuild tissue.

In a wound that will not close, those signals are weak, badly timed, or gone too soon.

Current treatments answer that with brute force. Sprays and creams flood the wound with large doses of manufactured growth factor drugs.

The proteins are fragile. Most break down or wash out of the wound before they can finish the job.

Other materials support the wound structurally but issue no biological instructions. The wound gets a scaffold and no directions.

The bill is large. Wounds that fail to heal cost the NHS billions a year, and burns alone kill about 180,000 people worldwide, most of them in low- and middle-income countries.

The body is not helpless here. It runs repair programs of its own, from muscle fibers that clear damaged parts after exercise to hair stem cells that switch to skin repair.

Wound dressing gets smart

The platform is built from aptamers – short strands of nucleic acid folded to grip one specific protein. They sit on a scaffold, usually a collagen sponge, placed in the wound.

The aptamers catch passing growth factors and concentrate them at the scaffold. Each one is held inactive, which also shields it from the enzymes that would otherwise destroy it.

The release trigger is force. When a repair cell migrates into the dressing and tugs, the grip loosens and the growth factor is handed to that cell, at that spot, at that moment.

Dr. Ben Almquist, the study’s senior author, is an associate professor in Bioengineering at Imperial. The team calls these constructs traction force activated payloads.

“What particularly stands out with this research is that the patient’s own body becomes the pharmacy,” said Dr. Almquist.

“We are not delivering a manufactured drug and hoping it survives long enough to work.”

“We are capturing what the body is already making and giving it back to the cells that need it, by encoding intelligence directly into the material, activated by the one signal guaranteed to be present right where healing is happening: the physical force of a cell pulling on its surroundings.”

Tested in living tissue

The concept first appeared in 2019, but only in simple cell cultures. That is a controlled environment, and nothing like the chemical mess of a real wound.

For the current study, the team ran it through three harder settings: rat bone injuries, mouse skin wounds, and living human skin kept alive in the laboratory.

In the rat bone model, sponges carrying the platform improved the growth of new blood vessels. In mouse skin, treated wounds were much smaller after ten days.

In living human skin, tissue grew into the dressing faster. In every setting, identical materials that could not be opened by cell pulling failed to match the effect.

Dr. Magdalene Ho of Imperial’s Department of Bioengineering is the lead author of the study.

“What excites me most is that this works in living human skin. We can see repair cells migrating into the wound dressing and confirm the material is engaging with human biology. That result makes me optimistic that this approach has a future in the clinic,” said Dr. Ho.

Doses far below clinical levels

The efficiency is what stands out in the numbers. The system works at doses hundreds to thousands of times lower than conventional growth factor delivery.

Against one growth factor product already in clinical use, the gap is more than 2,000-fold.

That is not only a cost argument. High doses of growth factor drugs have carried safety concerns for years, so getting the same effect from a sliver of protein matters.

The chemistry held up better than expected as well. Unmodified aptamers kept working in enzyme-rich wound fluid, which widens where nucleic acid therapies might be used.

The system can also be tuned so that only certain cell types release the cargo. That is a level of targeting sprays and creams cannot offer.

Limitations the study

No patient has been treated with this dressing. The evidence comes from rat bone, mouse skin, and human skin kept alive outside the body.

Laboratory human skin has no blood supply and no working immune system. Those are two of the things that go most wrong in a chronic wound.

The animals were healthy, too. The wounds that most need this technology sit on people with diabetes, poor circulation and years of accumulated damage.

The mouse result was measured over ten days, so nothing here speaks to scarring or long-term durability.

Healing beyond the cold chain

Because the dressing gathers its proteins from the wound or from blood, it could cut the need for manufactured drugs and the cold storage that keeps them stable.

That is a logistics advantage as much as a scientific one. It points at emergency medicine, humanitarian settings, frontline care and low-resource health systems.

Other groups are attacking the same problem from the sensing side, with a smart bandage that changes color when a wound becomes infected.

Mr. Shehan Hettiaratchy OBE, Professor of Practice in plastic and reconstructive surgery at Imperial College London, was not involved in the study.

“This is a major breakthrough in wound healing. We have known for a long time that the body is the best healer of wounds unless that system is disrupted,” said Professor Hettiaratchy.

“What this technology does is harness that system to get it back on track to heal wounds that the body is struggling to deal with.”

“This may have a huge impact on chronic wounds and also help ensure that acute wounds, such as from trauma or accidents, are optimized to heal from the start.”

The team is now talking to partners and clinicians about moving toward clinical use. The first real test will be a wound on a person rather than a wound in a dish.

The study is published in the journal Nature Materials.

—–

Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.

Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

—–